MicroRNAs in Lipid Metabolism and Atherosclerosis
Journal: The Indonesian Biomedical Journal (Vol.6, No. 1)Publication Date: 2014-04-01
Authors : Anna Meiliana; Andi Wijaya;
Page : 3-16
Keywords : Atherosclerosis; Lipoprotein; HDL; miRNA;
- MicroRNAs in Lipid Metabolism and Atherosclerosis
- The effect of herbal medicines on lipid metabolism and lipid peroxidation in experimental hyperlipidemia
- Altered Expression in Patients with Heart Failure of Circulating MicroRNAs Related to Lipoprotein Metabolism
- PARAMETERS OF LIPID METABOLISM AND SEVERITY OF LIVER STEATOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ON THE BACKGROUND OF HYPERTENSION DEPENDING ON THE STATUS OF CARBOHYDRATE METABOLISM
- CHANGES IN LIPID METABOLISM IN PATIENTS WITH DYSCIRCULATORY ENCEPHALOPATHY
Abstract
BACKGROUND: MicroRNAs (miRNA) are mediators of post-transcriptional gene expression that likely regulate most biological pathways and networks. The study of miRNAs is a rapidly emerging field; recent findings have revealed a significant role for miRNAs in atherosclerosis and lipoprotein metabolism. CONTENT: Results from recent studies demonstrated a role for miRNAs in endothelial integrity, macrophage inflammatory response to oxidized low-density lipoprotein, vascular smooth muscle cell proliferation and cholesterol synthesis. These mechanisms are all vital to the initiation and proliferation of atherosclerosis and cardiovascular disease. The importance of miRNAs has recently been recognized in cardiovascular sciences and miRNAs will likely become an integral part of our fundamental comprehension of atherosclerosis and lipoprotein metabolism. The extensive impact of miRNA mediated gene regulation and the relative ease of in vivo applicable modifications highlight the enormous potential of miRNA-based therapeutics in cardiovascular diseases. SUMMARY: miRNA studies in the field of lipid metabolism and atherosclerosis are in their infancy, and thus there is tremendous opportunity for discovery in this understudied area. The ability to target miRNAs in vivo through delivery of miRNA-mimics to enhance miRNA function, or antimiRNAs which inhibit miRNAs, has opened new avenues for the development of therapeutics for dyslipidemias and atherosclerosis, offers a unique approach to treating disease by modulating entire biological pathways. These exciting findings support the development of miRNA antagonists as potential therapeutics for the treatment of dyslipidaemia, atherosclerosis and related metabolic diseases.
Other Latest Articles
- An Empirically Derived Arc Flash Discharge Energy Model and Comparison to Established Safety Codes
- Optimization and Validation of a Real Time Reverse Transcriptase Polymerase Chain Reaction with RNA Internal Control to Detect Rubella RNA
- Association of Cross Linked C-Telopeptide II Collagen and Hyaluronic Acid with Knee Osteoarthritis Severity
- Caffeic Acid Inhibited Receptor Activator of Nuclear Factor kappaB Ligand (RANKL)-Tumor Necrosis Factor (TNF) alpha-TNF Receptor Associated Factor (TRAF) 6 Induced Osteoclastogenesis Pathway
- Correlation between Homeostatic Model Assessment-estimated Insulin Resistance (HOMA-IR) with Asymmetric Dimethylarginine (ADMA) in Prehypertension
Last modified: 2016-04-13 17:16:37